Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix, Sera Prognostics, Aspira, Epigenomics Post Q1 Financial Results

NEW YORK – A handful of molecular diagnostics companies reported first quarter results yesterday after the market closed and this morning. Below are brief reports on their results.

Biodesix reported revenues of $6.5 million for the first quarter ended March 31 compared to $28.9 million for Q1 2021, as COVID-19 testing sales plummeted year over year. The Boulder, Colorado-based firm, which makes diagnostic tests with a focus on lung diseases, posted core lung diagnostic revenue of $4.6 million versus $4.0 million for the same period in the prior year. Its COVID-19 test sales fell to $984,000 from $23.2 million. Its pharma services revenue also declined to $915,000 from $1.7 million year over year.

Biodesix posted a net loss of $15.6 million, or $.50 per share, compared to a loss of $7.0 million, or $.26 per share, for Q1 2021.

The firm finished the quarter with $16.4 million in cash and cash equivalents.

Sera Prognostics reported Q1 revenues of $38,000 for the three months ended March 31 versus $13,000 for the first quarter of 2021. The Salt Lake City-based firm, which sells the PreTRM proteomic test for predicting risk of preterm birth, posted a net loss of $12.2 million, or $.40 per share, compared to a loss of $6.4 million, or $3.55 per share, in Q1 2021. The company went public in July 2021, and as a result the weighted average shares it used to calculate its loss per share jumped from 1.8 million to 30.8 million year over year.

It finished the quarter with $64.1 million in cash and cash equivalents, and $43.5 million in marketable securities.

Aspira Women's Health reported that its first quarter revenues climbed to $1.9 million from $1.5 million for the period ended March 31. Its product revenue, which includes sales of its OVA1plus ovarian cancer test, accounted for almost all of those revenues. The number of OVA1plus tests performed increased 28 percent to 4,819 from 3,775 year over year.

Aspira's net loss jumped to $9.3 million, or $.08 per share, from $5.9 million, or $.05 per share, year over year, on higher R&D and SG&A spending.

Aspira finished the quarter with $26.9 million in cash and cash equivalents.

German molecular diagnostics firm Epigenomics reported a slight increase in Q1 revenues to €115,000 ($121,000) from €106,000. The maker of the blood-based Epi proColon test for early detection of colon cancer, posted a net loss of €2.7 million versus a loss of 1.2 million in Q1 2021. It reported cash and cash equivalents of 20 million as of March 31.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.